Abstract
BackgroundInterleukin-2 (IL-2) immunotherapies have revolutionized cancer treatment, but their clinical use is limited due to systemic adverse effects, such as vascular leakage syndrome.1 2 Notably, the high affinity of IL-2...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
